Telehealth

Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th

Retrieved on: 
Thursday, April 28, 2022
Capsule, U.S. Securities and Exchange Commission, Pregnancy, Software, Vaccine, Form 10-Q, Infection, Death, Patient, Eli Lilly and Company, Internet, FDA, GLOBE, Lilly, Collection, Interest, Private Securities Litigation Reform Act, COVID-19, Efficiency, Forward-looking statement, Flash, COVID, Company, Gonadotropin-releasing hormone, Telehealth, Zuclomifene, Security (finance), AR, Breast, Prostate cancer, Webcast, NASDAQ, Trial of the century, Fast Track, Finasteride, Prostate Cancer Foundation, Tadalafil, Insurance, Review, Government, CDK, Safety, Man, Pharmaceutical industry, Birth control, Medical imaging

MIAMI, April 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on Thursday, May 12, 2022, before the market opens.

Key Points: 
  • MIAMI, April 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on Thursday, May 12, 2022, before the market opens.
  • Verus management will host a conference call that same day at 8 a.m.
  • Interested parties may access the call by dialing 1-800-341-1602 from the U.S. or 1-412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call.
  • The call will also be available through a live, listen-only audio broadcast via the Internet at www.verupharma.com.

David Carmouche, MD, Senior Vice President, Omnichannel Care Offerings, Walmart Health, Added to Keynote Agenda for The Healthcare Innovation Congress

Retrieved on: 
Thursday, April 28, 2022
Walmart, Social determinants of health in poverty, CEO, LLC, Social determinants of health, Faculty, Policy, VP, Health care, Convenience, Content, Telehealth, Acquisition, Content strategy, VIP, Industry, Health, Medical device, Pharmaceutical industry, MD

BURLINGTON, Mass., April 28, 2022 /PRNewswire/ -- The Healthcare Innovation Congress (thINc360), taking place May 22-25 at the Hilton Baltimore Inner Harbor, announced that Dr. David Carmouche of Walmart Health has been added to its keynote agenda.

Key Points: 
  • BURLINGTON, Mass., April 28, 2022 /PRNewswire/ -- The Healthcare Innovation Congress (thINc360), taking place May 22-25 at the Hilton Baltimore Inner Harbor, announced that Dr. David Carmouche of Walmart Health has been added to its keynote agenda.
  • Dr. Carmouche leads omnichannel care delivery, including the Walmart Health centers, telemedicine through the acquisition of MeMD, and Walmart Health's push into value-based care.
  • Dr. Carmouche joins a speaking faculty of 100+ healthcare decision-makers and leaders who will share their insights on driving healthcare forward.
  • The Healthcare Innovation Congress, organized by The Healthcare Innovation Company, gathers cross-sector healthcare leaders for the year's most prominent industry event.

Caregility Launching New Subscription-Based Enterprise Telehealth Solution and Low-Acuity Virtual Care Endpoint at ATA2022

Retrieved on: 
Wednesday, April 27, 2022
Cloud, American Telemedicine Association, LinkedIn, Houston Methodist Hospital, Association, ATA, Twitter, Patient, Telehealth, HIPAA, Efficiency, IVE, Massachusetts General Hospital, Hospital, APS, Safety, Medicine

EATONTOWN, N.J., April 27, 2022 /PRNewswire/ -- Caregility, an enterprise telehealth market leader dedicated to connecting care for patients and clinicians everywhere, will launch new offerings to enable system-wide telehealth across all inpatient acuity settings at the 2022 American Telemedicine Association conference in Boston, May 1-3. Caregility's Inpatient Virtual Engagement (IVE) solution bundles: 

Key Points: 
  • IVE extends virtual bedside access across the continuum of care to enhance in-person encounters and elevate the patient and clinician experience.
  • Enterprise-wide telehealth solutions like IVE create the foundation required to support telenursing models, including but not limited to virtual rounding, virtual observation , and virtual specialty coverage .
  • Designated as the Best in KLAS Virtual Care Platform (non-EMR) in 2021 and 2022, CaregilityCloud powersa purpose-built ecosystem of enterprise telehealth solutions across the care continuum.
  • Caregility supports more than 1,300 hospitals across dozens of health systems with millions of virtual care sessions hosted annually.

Northwell Health Deploys Telemedicine to Ukraine’s Eastern Front

Retrieved on: 
Wednesday, April 27, 2022
Technology, Medical Supplies, Telecommunications, Philanthropy, Other Health, Health, General Health, Other Philanthropy, Foundation, Transfer, CEO, Government, Medicine, COVID-19, Tablet, Twitter, Medical research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, MD, Center, Trauma, Hospital, Education, Patient, Telehealth, LinkedIn, Médecins Sans Frontières, Global Health, Feinstein Institute for Medical Research, Instagram, Coronavirus, Multimedia, Physician, Nursing, COVID, Ohio State University Health Sciences Center for Global Health, Health, Emergency medicine, CGH, Health insurance, Northwell Health, Facebook

As Russian forces engage in a second offensive on the eastern border of Ukraine, Northwell Health is providing telemedicine support to aid these frontline regions.

Key Points: 
  • As Russian forces engage in a second offensive on the eastern border of Ukraine, Northwell Health is providing telemedicine support to aid these frontline regions.
  • In February, Northwell aligned with Doctors Without Borders , an organization with extensive experience in combat medicine and humanitarian relief across the globe.
  • Northwell Health is New York States largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians.
  • Our 79,000 employees 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners are working to change health care for the better.

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, ATTD, Medicine, Biotechnology, Graduate University of Advanced Technology, U.S. Securities and Exchange Commission, Type 1, IND, Software, NASDAQ, PMCB, Pancreatic cancer, Private Securities Litigation Reform Act, Diabetes, Capsule, Hospital, Form 10-K, Neoplasm, Conference, Ifosfamide, Telehealth, Technology, Form, Informatics, Insulin, Algorithm, Intelligence, Immortalised cell line, FDA, International Conference on Information Systems Security and Privacy, Liver, Cell, Cancer, Pharmaceutical industry, Medical device, Medical imaging

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022, in Barcelona, Spain.

Key Points: 
  • PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022, in Barcelona, Spain.
  • The meetings at the conference have become the most renowned forum worldwide for presenting developments in new diabetes technologies and treatments.
  • PharmaCytes Chief Executive Officer, Kenneth L. Waggoner, said, This annual conference is where clinicians, diabetes care providers, researchers, industry leaders and investors come together to share knowledge and develop collaborations.
  • Our live-cell encapsulation-based treatment offers real hope for future development in the field of diabetes.

New Studies Demonstrate Clinical Benefits of Patient- and Provider-Supportive Technology in Diabetes Management

Retrieved on: 
Wednesday, April 27, 2022
ATTD, Health, T1D, Technology, OTR, Journal of Diabetes Science and Technology, Adoption, Telephone, Obesity, COVID-19, Blood, Bluetooth, Research, Weight loss, Diagnosis, Caregiver, A1C, Treatment, Patient, Conference, Type 2 diabetes, Telehealth, Overweight, T2D, HCPS, Global Medical Device Nomenclature, BGM, Solution, American Association of Clinical Endocrinologists, Method, Journal, Meal, Multimedia, International Conference on Information Systems Security and Privacy, Quality of life, HCP, Prevalence, COVID, OneTouch Ultra, Trust, Honda advanced technology, Medical device, Pharmaceutical industry, Satellite navigation device, Mobile phone, Safety, Acnalbasac Noom, LifeScan, Diabetes

MALVERN, Pa., April 27, 2022 /PRNewswire/ -- LifeScan, a world leader in blood glucose monitoring, announced today the presentation of three studies showing the value of app-based technology in improving diabetes management. The three studies, presented at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), examined the use of different technologies in various patient populations, and all similarly concluded that a clear benefit was observed for healthcare providers and patients with diabetes.

Key Points: 
  • A second study analyzed the benefit of 16 weeks of free access to Noom's app-based weight loss program for people living with type 2 diabetes.
  • "Our goal at LifeScan is to offer people living with and treating diabetes the digital tools and connected solutions that can make its management easier and more successful.
  • Blood glucose monitors (BGM) are vital for over 95% of people with diabetes who monitor their blood glucose.
  • The aim was to understand the impact digital diabetes management solutions, like OTR, had during the pandemic.

IMPLICITY Raises $23M to Broaden Use of Its Cardiac Remote Monitoring Platform

Retrieved on: 
Wednesday, April 27, 2022
COVID-19, Cardiology, CEO, Investment, Adoption, Conditional sentence, Degenerative disease, Research, List, Diagnosis, SME, Patient, Growth, Efficiency, Mental health, Technology, Telehealth, Health, Solution, AI, Algorithm, Intelligence, Lan Xang, Medtech, Diabetes, Heart, FDA, Cancer, Disease, Knowledge, Medical device, Renewable energy, Bpifrance, Series

CAMBRIDGE, Mass., April 27, 2022 /PRNewswire/ -- IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today announced it has raised $23 million in Series A funding led by new investors: Crédit Mutuel Innovation and Bpifrance.

Key Points: 
  • In order to democratize remote cardiac care, our mission is to provide healthcare professionals with the best technology available to scale and monitor all cardiac patients," said Dr. Arnaud Rosier, CEO and founder of IMPLICITY.
  • We believe the company has the potential to become a world-class leader in cardiac remote monitoring.
  • IMPLICITYis a software company that provides a universal cardiac remote monitoring and research platform to clinics and service companies, helping them provide the best remote care to cardiac patients.
  • The IMPLICITY platform aggregates, normalizes and standardizes data from all implantable cardiac electronic device across all major manufacturers.

North American Clinical Documentation Improvement Market Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Technology, Nursing, Hospitals, Security, Software, Internet, Managed Care, Health, Data Management, HIT, Gaps, Clinical trial, Population, COVID-19, EMR, Roger Hawkins (drummer), CDI, Automation, Subclinical infection, Program, RCM, Machine learning, Artificial intelligence, Budget, Telehealth, Solution, Acquisition, Natural language processing, Medical device, Medicine

The "North American Clinical Documentation Improvement Market 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North American Clinical Documentation Improvement Market 2022" report has been added to ResearchAndMarkets.com's offering.
  • The overall goal of any CDI program is to improve clinical documentation, coding, and reimbursement.
  • Solution providers are reimagining tools that pave the way for next-generation clinical documentation across the healthcare continuum.
  • Accurate, comprehensive, and ethnic-appropriate clinical documentation will help providers standardize reimbursement and opt for payment exceptions for specific population health management initiatives.

Joslin Diabetes Center Collaborates with Cecelia Health to Improve Continuous Glucose Monitor (CGM) Adoption Among Older Adults with Diabetes

Retrieved on: 
Tuesday, April 26, 2022
State University of New York Upstate Medical University, Awareness, T1D, Metabolism, Adoption, American Diabetes Association, Longwood Medical Area station, Faculty, Population, Rosalind Franklin University of Medicine and Science, Geriatrics, Research, Health, REST, Joslin Diabetes Center, Element, Education, Diabetes, Patient, Sustainable Development Technology Canada, Life expectancy, Program, Leona, Central, Longwood Medical and Academic Area, Technology, Telehealth, Hypoglycemia, Insurance, CGM, Joslin, Ready, Set, PrEP, Sustainability, LMA, Conditional sentence, Public Health Service Distinguished Service Medal, Critical care, Assistant, The Leona M. and Harry B. Helmsley Charitable Trust, Harvard Medical School, Risk, Quality of life, Pharmaceutical industry, Medical device, Hospital, Helmsley, Medicine, Endocrinology, Science

NEW YORK, April 26, 2022 /PRNewswire-PRWeb/ -- Cecelia Health and Joslin Diabetes Center today announced a collaborative program to address and overcome barriers to the initiation and use of continuous glucose monitoring (CGM) in older adults with diabetes on complex insulin regimens. The study, building on Joslin Diabetes Center's previous work with this patient population, is funded by a grant from The Leona M. and Harry B. Helmsley Charitable Trust.

Key Points: 
  • One of the tools shown to improve glycemic control and reduce risk of hypoglycemia when used appropriately is real-time CGM.
  • This project is a collaboration between the Joslin Diabetes Center teams in Boston, Massachusetts and Syracuse, New York, and Cecelia Health's national remote care team.
  • "This is a tremendous opportunity to partner with Joslin Diabetes Center to support this vulnerable population of older adults on complex diabetes regimens and (potentially) establish a new standard in remote diabetes care.
  • The Joslin Diabetes Center affiliate at SUNY Upstate Medical University, located in Syracuse NY, provides Central NYS communities excellence in patient care, education and research in diabetes.

Iris Telehealth Engages Amendola for Strategic PR and Media Relations Services

Retrieved on: 
Tuesday, April 26, 2022
STAT, Awareness, Public relations, Technology, Marketing, COVID-19, Twitter, The A-Team, Leadership, Hospital, Iris, News, Patient, LinkedIn, Community, ROI, Mental health, Telehealth, Social media, Health, PR, Danny Amendola, Axios, Public health, Industry, Overalls, Pharmaceutical industry, Medicine, Fortune

SCOTTSDALE, Ariz., April 26, 2022 /PRNewswire/ -- Amendola Communications, a nationally recognized, award-winning healthcare and technology marketing and public relations firm, announced that Iris Telehealth, a leading provider of telepsychiatry services for community mental health centers, community health centers, hospitals, and health systems across the U.S., has selected the firm to manage PR, media relations, and thought leadership. Iris conducted an extensive agency search and selected Amendola for its successful track record, industry acumen, and bench strength.

Key Points: 
  • Iris conducted an extensive agency search and selected Amendola for its successful track record, industry acumen, and bench strength.
  • "Providing easy and convenient access to accredited psychiatric services from quality behavioral health professionals is essential to this effort.
  • Amendola is implementing a comprehensive public relations, thought leadership, communications, and media plan for Iris Telehealth that will showcaseits value proposition, services, accomplishments, customer wins, and industry partnerships.
  • Amendola is an award-winning, insights-driven public relations and marketing firm that integrates media relations, social media, content, and lead gen programs to move healthcare, life sciences/pharma and healthcare IT decision-makers to action.